Atopic dermatitis (AD) in older adults (elderly AD) has recently emerged as a newly defined
subgroup of AD. When selecting treatment options, clinical characteristics of elderly AD and …

Background Treatment of moderate‐to‐severe atopic dermatitis (AD) in the elderly may be
challenging, due to side‐effects of traditional anti‐inflammatory drugs and to comorbidities …

Objective The objective of this study was to assess the effectiveness and safety of dupilumab
in treating elderly patients with atopic dermatitis from baseline to 52 weeks. Methods A …

Atopic dermatitis (AD) in older adults represents a newly defined subgroup of AD. The
prevalence of elderly AD is approximately 1–3% among elderly populations in industrialized …

Background Adults aged≥ 60 years are often underrepresented in atopic dermatitis (AD)
clinical trials; age-related comorbidities may impact treatment efficacy and safety. Objective …

Atopic dermatitis (AD) in the elderly has recently emerged as a distinct subgroup of AD,
garnering widespread concern due to its increasing global incidence rate. Epidermal barrier …

Though atopic dermatitis (AD) is relatively uncommon in the elderly, elderly patients with AD
are gradually increasing in industrialized countries associated with an aging society …

Background Clinical trials of systemic therapies for atopic dermatitis (AD) often exclude
patients based on age and comorbidities. Objectives We conducted a scoping review of …

Background: The clinical features of adult-onset atopic dermatitis (AD) are heterogeneous
and the diagnosis can be a challenge. A new biologic drug (dupilumab) has been approved …

Background Atopic dermatitis (AD) is a multifactorial and complex disease, characterized by
an impaired skin barrier function and abnormal immune response. Many elderly patients …